Canada: Will New Trademark Regime Raise The Bar?

Last Updated: July 11 2016
Article by Susan Keri and Meghan Dillon

The new Trademarks Act's registration requirements and provisions on distinctive marks look set to have a significant impact on how pharmaceutical companies manage their trademark strategies

Canada continues to await implementation of amendments to the Trademarks Act set out in Bill C-31, the Economic Action Plan 2014 Act (No 1). The bill received royal assent in June 2014 and is expected to be implemented in 2018. The stated goal of the amendments is to bring Canada into line with international practice, allowing it to accede to the Madrid Protocol, the Singapore Treaty and the Nice Agreement. The legislative amendments are likely to present both benefits and challenges for applicants in all industries, with the pharmaceutical industry being no exception.

Dispensation of use as registration requirement

The most notable change to be introduced by Bill C-31 – and the one that has received the greatest amount of attention – is the dispensation of use as a requirement for registration.

At present, trademark applications must be based on at least one filing ground. The most common filing bases are:

  • use in Canada;
  • proposed use in Canada; and
  • use and registration abroad.

While an application can be filed in Canada on the basis of an intention to use in the country, it will not issue to registration until a declaration of use is filed attesting to commercial use of the mark in Canada. The registration will issue only for those goods or services for which the mark has been put into commercial use within Canada.

The requirement of having to file a declaration of use to secure registration is often particularly onerous for pharmaceutical trademarks. Pharmaceutical products cannot be sold in Canada until the drug has been approved by Health Canada, and ordinarily neither sample shipments nor use of the mark in the context of clinical trials constitutes trademark use sufficient to support the filing of a declaration of use. Given the lengthy drug approval process in the country, there is often a long delay between the allowance of a pharmaceutical trademark application and the filing of a declaration of use, necessitating the filing of multiple extensions. Indeed, applications must often be re-filed altogether once the maximum allowable extension period has expired.

Once the amendments to the act are implemented, trademark application filing grounds will be eliminated and applicants need only be "using or propose to use, and be entitled to use" the applied-for mark in Canada. Under the new regime, applications will issue to registration simply on expiry of the opposition period, regardless of whether use has commenced in Canada or anywhere else in the world. This means that trademarks covering pharmaceutical products could issue to registration long before the products are approved for sale by Health Canada. Further, the elimination of use as a prerequisite to registration will enable pharmaceutical companies to secure trademark registrations for marks covering virtually all types of pharmaceutical product and service, without ever having used the mark in Canada.

Non-traditional marks and examination for distinctiveness

While the dispensation of use as a prerequisite to registration is likely to be a welcome change in the pharmaceutical field, other amendments may not be so favourable.

Under the existing regime, there is no examination for distinctiveness, with the exception of distinguishing guise applications (ie, the shape of the goods or their packaging), where applicants are required to file evidence of distinctiveness. The amendments eliminate the concept of a distinguishing guise as a distinct type of trademark, replacing it with an expanded definition of 'trademark' to include various non-traditional marks. While this represents a significant shift towards acceptance of a wider variety of non-traditional marks (eg, scents, tastes and textures), applications to register non-traditional marks – and indeed all marks – will be subject to examination for distinctiveness. If the registrar is of the view that an applied-for mark is not inherently distinctive, the applicant will be required to file evidence that the mark had acquired distinctiveness across Canada as of the trademark application filing date, and the registration will be restricted to the provinces and territories in Canada where the mark has been shown to be distinctive.

Examination for distinctiveness will be particularly relevant in the pharmaceutical field where trademark protection is often sought for non-traditional marks such as the colour of pharmaceutical tablets or capsules. Colour marks are considered inherently registrable in Canada (Smith, Kline & French v Registrar, [1987] 2 FC 633) and are not currently subject to examination for distinctiveness. However, under the new trademark regime, evidence of distinctiveness will be required for applications to register all non-traditional marks, including colour marks.

Oppositions and litigation in Canada demonstrate how difficult it is for pharmaceutical companies to establish that non-traditional marks (eg, colour tablets or capsules) have become distinctive. There is concern that the same high threshold for establishing distinctiveness will be applied at the examination stage, once the new regime is implemented, making it both more expensive and more difficult for such marks even to reach the opposition phase, let alone make it through to registration.

The recent Federal Court decision in Pfizer Products Inc v Canadian Generic Pharmaceutical Assoc (2015 FC 493) highlights the high evidential burden on an applicant in establishing that colour applied to a pharmaceutical tablet or capsule serves to distinguish the rights holder's goods from those of others. The case dealt with Pfizer's application to register a trademark consisting of the colour blue applied to the whole of the visible surface of a diamond-shaped tablet. The application was successfully opposed by the Canadian Generic Pharmaceutical Association. The Trademarks Opposition Board held while the Viagra tablet design was distinctive among patients, Pfizer had failed to establish that it was also distinctive among physicians and pharmacists – all part of the relevant consumer group.

Pfizer appealed the decision, arguing that the board had erred in its application of the test for distinctiveness by requiring that distinctiveness be established among patients, physicians and pharmacists.

The Federal Court upheld the Trademarks Opposition Board's decision that the Viagra tablet design was not distinctive of Pfizer or any single source. The court agreed that distinctiveness need not be established in each of the consumer sub-groups, but rather that a significant degree of recognition among the whole constituency of ordinary consumers – including physicians, pharmacists and patients – was required. However, it nevertheless found that the limited use which physicians, pharmacists and patients made of the appearance of the Viagra tablet design for identification purposes was insufficient to establish the distinctiveness required for trademark registration.

The case confirms that the test for distinctiveness is the same in the pharmaceutical industry as in any other: the applicant must show on a balance of probabilities that the relevant consumer associates the trademark with a single source to a significant degree. However, in the pharmaceutical context, where the relevant consumer includes patients who use the products, physicians who prescribe them and pharmacists who dispense them, and where purchasing decisions are usually made by professionals or on the advice of professionals, the distinctiveness of such marks will be inherently more difficult to establish.

Given the difficult threshold for establishing distinctiveness of non-traditional marks in the pharmaceutical field and the fact that these types of application are virtually always opposed, examination for distinctiveness will simply add a further hurdle, making it even more difficult to register non-traditional marks such as colour tablets or capsules in the pharmaceutical industry.

Previously published in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Susan Keri
Meghan Dillon
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions